- Home
- VFC vs RYTM Comparison
VFC vs RYTM Comparison
Compare VFC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VFC | RYTM |
|---|---|---|
| Founded | 1899 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | VFC | RYTM |
|---|---|---|
| Price | $19.48 | $113.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $16.13 | ★ $125.77 |
| AVG Volume (30 Days) | ★ 6.0M | 887.7K |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $9,541,055,000.00 | $174,334,000.00 |
| Revenue This Year | $0.66 | $47.34 |
| Revenue Next Year | $0.96 | $57.18 |
| P/E Ratio | $84.84 | ★ N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $9.41 | $45.91 |
| 52 Week High | $29.02 | $122.20 |
Technical Indicators
Market Signals| Indicator | VFC | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 68.05 | 58.01 |
| Support Level | $18.06 | $109.59 |
| Resistance Level | $20.30 | $122.20 |
| Average True Range (ATR) | 0.81 | 5.23 |
| MACD | 0.15 | 1.07 |
| Stochastic Oscillator | 79.27 | 55.91 |
Price Performance
Historical ComparisonAbout VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.